TransCure bioServices has acquired TransCure bioServices for an undisclosed amount. This corporate transaction consolidates the preclinical research specialist under a unified structure, reinforcing its commitment to accelerating drug development through advanced in vivo models.
The acquired entity, TransCure bioServices, is known for rethinking preclinical research by delivering robust, translational in vivo results. It specializes in advanced humanized mouse models to guide decision-making across oncology, inflammatory diseases, and infectious diseases & toxicity. With over 12 years of experience, the company co-designs studies with partners to fit their strategy, timelines, and regulatory requirements. Operating from AAALAC-accredited, BSL-2 & BSL-3 facilities in France, TransCure bioServices supports biotech, pharma, and academic partners worldwide from discovery to clinical readiness, adhering to the 3Rs (Reduce, Refine, Replace) for ethical and impactful science.
This acquisition is a strategic move to streamline operations and enhance the company's market position as a leader in preclinical research. By formally integrating all aspects of its business under a single corporate umbrella, TransCure bioServices aims to achieve greater operational efficiencies and foster deeper synergies across its service offerings. The consolidation is expected to strengthen its capacity to provide tailored solutions and maintain the highest standards of quality and animal welfare, ensuring partners continue to receive precise data and expert partnership.
Looking ahead, the combined entity will continue its mission to accelerate drug development. This strategic alignment positions TransCure bioServices to further innovate its model platforms and expand its global reach, ensuring it remains a pivotal partner in bringing new therapies to patients.